Increasing Demand for Next-Generation Sequencing in Companion Diagnostics

The global companion diagnostic market is expected to reach USD 6.51 Billion by 2022 from USD 2.61 Billion in 2017, at a CAGR of 20.1%.

(EMAILWIRE.COM, August 04, 2018 ) Browse 105 Market Data Tables and 37 Figures spread through 170 Pages and in-depth TOC on "Companion Diagnostics Market by Technology (PCR, IHC, NGS, ISH), Indication (Breast cancer, NSCLC, Colorectal cancer, Neurological disorders, Infectious Diseases), End User (Pharmaceutical & Biopharmaceutical Companies, Reference Lab) - Global Forecast to 2022"

https://www.marketsandmarkets.com/Market-Reports/companion-diagnostics-market-155571681.html
Early buyers will receive 10% customization on this reports

Based on technology, the polymerase chain reaction (PCR) segment accounted for the largest share of the market in 2016

On the basis of technology, the companion diagnostics market is broadly segmented into polymerase chain reaction (PCR), in situ hybridization (ISH), immunohistochemistry (IHC), next-generation sequencing (NGS), and other technologies. In 2016, the polymerase chain reaction (PCR) segment accounted for the largest share of this market and the next-generation sequencing (NGS) segment is expected to register the highest CAGR during the forecast period. The large share of the PCR segment is attributed to its ease of use and to the fact that it does not require many samples for biomarker identification.

Based on indication of companion diagnostics market, the oncology segment held the largest market share in 2016

Based on the indication, the global companion diagnostics market is divided into oncology, infectious diseases, neurology, and other indications. The oncology segment is expected to account for the largest share of the global companion diagnostics market by indication. It is also the fastest growing segment owing to the increasing cases of cancer cases across the globe and the rising number of clinical trials targeting cancer biomarkers for lung, breast, and prostate cancers.

Press release : https://www.prnewswire.com/news-releases/companion-diagnostics-market-to-reach-usd-651-billion-by-2022-637833923.html

The key players in the global companion diagnostics market are Roche Diagnostics (Switzerland), Agilent Technologies, Inc. (U.S.), QIAGEN N.V. (Netherlands), and Abbott Laboratories Inc. (U.S.).

Target Audience:

Pharmaceutical and biotechnology companies
Diagnostic manufacturers
Research laboratories and academic institutes
Research and development (R&D) companies
Clinical research organizations (CROs)

Download PDF Brochure : https://www.marketsandmarkets.com/pdfdownload.asp?id=155571681

Scope of the Report:

The research report categorizes the global market into the following segments and subsegments:

Companion Diagnostics Market, by Product & Service

Assays & Reagents
Software & Services
Companion Diagnostics Market, by Indication

Oncology
Breast Cancer
Lung Cancer
Colorectal Cancer
Melanoma
Gastric Cancer
Other Types of Cancer
Infectious Diseases
Neurology
Other Indications
*Other indications include cardiovascular diseases, inflammatory diseases, and inherited diseases

Companion Diagnostics Market, by Technology

Polymerase Chain Reaction (PCR)
Immunohistochemistry (IHC)
In Situ Hybridization (ISH)
Next-generation Sequencing
Other Technologies
*Other technologies include multiplex assay and imaging technology.

Companion Diagnostics Market, by End User

Pharmaceutical and Biopharmaceutical Companies
Reference Lab
Other End User
*Other end users include CROs, physician labs, hospital labs, and academic medical centers

Companion Diagnostics Market, by Region

North America
U.S.
Canada
Europe
Germany
U.K.
France
Rest of Europe (RoE)
Asia-Pacific
RoW